Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

498 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
Gounder MM, Bauer TM, Schwartz GK, Weise AM, LoRusso P, Kumar P, Tao B, Hong Y, Patel P, Lu Y, Lesegretain A, Tirunagaru VG, Xu F, Doebele RC, Hong DS. Gounder MM, et al. Among authors: hong ds, hong y. J Clin Oncol. 2023 Mar 20;41(9):1714-1724. doi: 10.1200/JCO.22.01285. Epub 2023 Jan 20. J Clin Oncol. 2023. PMID: 36669146 Free PMC article. Clinical Trial.
A first-in-human study of conatumumab in adult patients with advanced solid tumors.
Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, LoRusso PM. Herbst RS, et al. Among authors: hong ds. Clin Cancer Res. 2010 Dec 1;16(23):5883-91. doi: 10.1158/1078-0432.CCR-10-0631. Epub 2010 Oct 14. Clin Cancer Res. 2010. PMID: 20947515 Clinical Trial.
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Müller T, Ratain MJ, Salgia R. Kurzrock R, et al. Among authors: hong ds. J Clin Oncol. 2011 Jul 1;29(19):2660-6. doi: 10.1200/JCO.2010.32.4145. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606412 Free PMC article. Clinical Trial.
Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.
Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, Rohren E, Ng C, Chandhasin C, LoRusso P. Naing A, et al. Clin Cancer Res. 2011 Sep 15;17(18):6052-60. doi: 10.1158/1078-0432.CCR-10-2979. Epub 2011 Jul 12. Clin Cancer Res. 2011. PMID: 21750201 Free PMC article. Clinical Trial.
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Naing A, et al. Among authors: hong ds. Clin Cancer Res. 2012 May 1;18(9):2625-31. doi: 10.1158/1078-0432.CCR-12-0061. Epub 2012 Mar 31. Clin Cancer Res. 2012. PMID: 22465830 Free PMC article. Clinical Trial.
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. Hong DS, et al. Clin Cancer Res. 2012 Aug 1;18(15):4173-82. doi: 10.1158/1078-0432.CCR-12-0714. Epub 2012 Jun 12. Clin Cancer Res. 2012. PMID: 22693357 Clinical Trial.
498 results